Barclays’s Core Laboratories CLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,700
| Closed | -$26K | – | 4914 |
|
|
2020
Q3 | $26K | Sell |
1,700
-1,000
| -37% | -$21K | ﹤0.01% | 4846 |
|
|
2020
Q2 | $55K | Sell |
2,700
-25,200
| -90% | -$452K | ﹤0.01% | 4883 |
|
|
2020
Q1 | $288K | Buy |
27,900
+12,100
| +77% | +$338K | ﹤0.01% | 4025 |
|
|
2019
Q4 | $595K | Buy |
15,800
+2,600
| +20% | +$117K | ﹤0.01% | 4142 |
|
|
2019
Q3 | $615K | Sell |
13,200
-300
| -2% | -$13.9K | ﹤0.01% | 4082 |
|
|
2019
Q2 | $706K | Buy |
13,500
+8,200
| +155% | +$481K | ﹤0.01% | 4029 |
|
|
2019
Q1 | $365K | Sell |
5,300
-6,800
| -56% | -$456K | ﹤0.01% | 4362 |
|
|
2018
Q4 | $722K | Buy |
12,100
+8,600
| +246% | +$742K | ﹤0.01% | 3444 |
|
|
2018
Q3 | $405K | Sell |
3,500
-37,500
| -91% | -$4.23M | ﹤0.01% | 4446 |
|
|
2018
Q2 | $5.17M | Buy |
41,000
+40,400
| +6,733% | +$4.92M | ﹤0.01% | 1698 |
|
|
2018
Q1 | $65K | Sell |
600
-900
| -60% | -$99.6K | ﹤0.01% | 5683 |
|
|
2017
Q4 | $164K | Buy |
+1,500
| New | +$150K | ﹤0.01% | 4854 |
|
|
2017
Q3 | – | Sell |
-1,600
| Closed | -$162K | – | 6856 |
|
|
2017
Q2 | $162K | Sell |
1,600
-700
| -30% | -$75.5K | ﹤0.01% | 4538 |
|
|
2017
Q1 | $266K | Sell |
2,300
-2,500
| -52% | -$291K | ﹤0.01% | 4038 |
|
|
2016
Q4 | $576K | Sell |
4,800
-8,100
| -63% | -$897K | ﹤0.01% | 3247 |
|
|
2016
Q3 | $1.45M | Buy |
12,900
+6,300
| +95% | +$726K | ﹤0.01% | 2275 |
|
|
2016
Q2 | $818K | Buy |
6,600
+1,300
| +25% | +$157K | ﹤0.01% | 2792 |
|
|
2016
Q1 | $594K | Sell |
5,300
-4,000
| -43% | -$416K | ﹤0.01% | 3003 |
|
|
2015
Q4 | $1M | Buy |
9,300
+3,300
| +55% | +$378K | ﹤0.01% | 2612 |
|
|
2015
Q3 | $594K | Sell |
6,000
-16,300
| -73% | -$1.77M | ﹤0.01% | 3205 |
|
|
2015
Q2 | $2.54M | Sell |
22,300
-198,200
| -90% | -$24M | ﹤0.01% | 2032 |
|
|
2015
Q1 | $22.9M | Buy |
220,500
+16,600
| +8% | +$1.77M | 0.03% | 612 |
|
|
2014
Q4 | $24.5M | Buy |
203,900
+182,200
| +840% | +$23.9M | 0.02% | 659 |
|
|
2014
Q3 | $3.17M | Buy |
21,700
+10,300
| +90% | +$1.59M | ﹤0.01% | 2230 |
|
|
2014
Q2 | $1.9M | Sell |
11,400
-1,700
| -13% | -$302K | ﹤0.01% | 2653 |
|
|
2014
Q1 | $2.59M | Buy |
13,100
+8,700
| +198% | +$1.64M | ﹤0.01% | 2290 |
|
|
2013
Q4 | $836K | Buy |
4,400
+2,800
| +175% | +$521K | ﹤0.01% | 3575 |
|
|
2013
Q3 | $270K | Sell |
1,600
-2,100
| -57% | -$326K | ﹤0.01% | 4750 |
|
|
2013
Q2 | $561K | Buy |
+3,700
| New | +$524K | ﹤0.01% | 4068 |
|
Other funds holding CLB
AI
DGI
CAMG
VCM
VPM
Barclays's CLB Position: Q1 2026 in Review
Barclays reduced its Core Laboratories (CLB) stake by 88% in Q1 2026, selling an estimated $1.15M and leaving 8,955 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3844.
Barclays first reported a position in CLB in Q2 2013 and has held it in 51 quarters since. The position peaked at $36M in Q2 2018. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.
- Barclays held 8,955 shares of Core Laboratories worth $150K as of Q1 2026.
- Barclays sold 64,291 Core Laboratories shares in Q1 2026, an estimated $1.15M.
- Core Laboratories made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3844 holding.
- Barclays first reported a position in Core Laboratories in Q2 2013 and has held it in 51 quarters since.
- Barclays's Core Laboratories position peaked at $36M in Q2 2018.
- 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.